Key Highlights

Financials

₹166417 Mn

Total Revenue From Operations

₹18715 Mn

EBITDA

Rankings

#3

in the U.S. (by prescriptions)

#6

in Indian Pharma Market

R&D

911

Active Patents

463

ANDAs filed with U.S. FDA
until March 2023

PRODUCTS

30+

Robust Pipeline of Injectables

29 Bn

Formulation Units Sold Globally (IQVIA MAT Mar 23 Standard Units)

625000+

Patients Reached Through
Patient Education Programs

15000+

HCPs Participated in
Doctor Education Programs

8% YoY

Reduction in Scope 1 and
Scope 2 Emissions in FY23

Reflections
from the top

Letter from
Chairman

READ MORE

Letter from
CEO and MD

READ MORE

Letter from
CFO

READ MORE

Our
ESG Goals

ESG objectives are strategic in design and holistic to ensure we effectively contribute to both enterprise value creation and improving the environment, society, and economy. These include both short-term and long-term targets.

Product Accessibility and Affordability
Access to Medicines
  • Targeting 80+ registrations of anti-TB and ARV medicines in 2024
Implementation of Patient Assistance Programs
  • Two programs by 2025, benefitting 100,000 patients each
Education for Patients and Doctors
  • Touching 1 million Patients by 2028 and 20,000 doctors by 2030
Local Manufacturing Partnership
  • Developing partnerships in African firm by 2027 to improve accessibility
Capital


Material Issues
  • Accessibility and Affordability
  • Community Development and CSR
Complex Generics Launches in Regulated Markets by 2028
  • 20 complex product launches in the areas of inhalation, injectables, among others
Biosimilar and Novel Complex Products
  • Complete 3 biosimilar filings in regulated markets by 2028
  • Launch 10 novel complex pipeline products in India by 2028
Process/Open Innovations
  • Target 15-20 process innovations annually, resulting in $2-3 million in savings
  • Pursue open innovation partnerships in API, formulations, digital solutions, and diagnostics
Capital


Material Issues
  • Innovation Management and Research
  • Digitization
Regulatory Compliance
  • Zero sites with Warning Letter status (WL) by FY25
Recalls
  • Maintain zero class I recalls
Data Integrity
  • No data integrity-related observations in any regulatory audits
Quality Audits
  • Lupin’s India sites undergo annual audits, while supplier sites are audited every three years and during vendor qualification
CGMP Training
  • Ensure 100% completion of mandatory training to applicable employees
Capital


Material Issues
  • Regulatory Compliance, Consumer and Patient Safety & Pharmacovigilance
  • Data Integrity, Data Privacy and Cyber Security
Diagnosis
  • By 2030, assist in the diagnosis of lung disease using fractional exhaled nitric oxide (FENO) and Spirometry tests for more than 10 million patients
  • Target the diagnosis of breast cancer in 1,400 women in FY24
Rehabilitation
  • “Lungs on Care” campaign: Provide in-clinic services for Interstitial Lung Diseases (ILD) rehabilitation in 300 clinics by 2030
  • Atharv Ability, our neuro rehabilitation center is targeting an outreach to 10,000 patients in FY24
Full care
  • Lyfe provides post ACS (acute coronary syndrome) patient care, aiming to reach 25,000 patients in FY24
Capital


Material Issues
  • Community Engagement and Development
  • Regulatory Compliance, Consumer and Patient Safety & Pharmacovigilance
  • Data Integrity, Data Privacy and Cyber Security
Greenhouse Gas Emissions
  • By 2030, reduce Scope 1 and Scope 2 GHG emissions by 15% from 2019-20 levels
Water Conservation
  • By 2025, we aim to recycle 50% of our total water withdrawal
Hazardous Waste Management
  • By 2025, re-direct 60% of incinerable hazardous waste from Indian operations to co-processing such as cement plants
Regularly review and revise goals
  • In alignment with our decarbonization strategy and Scope 3 reduction objectives
Capital


Material Issues
  • Environmental Impact Management
  • Climate Change and Impact on Business
  • Opportunities in Renewable Energy
  • Opportunities in Green Building
  • Antimicrobial Resistance
ESG Databook

Our
Capitals

Financial
Capital

Read More

Manufactured
Capital

Read More

Intellectual
Capital

Read More

Social and
Relationship Capital

Read More

Human
Capital

Read More

Natural
Capital

Read More
Download Reports

INTEGRATED REPORT
2022 - 2023

Download
ESG
Our Impact
Overview
MD&A
Reports & Financials Assurance Statement